Hrt Financial LP Geron Corp Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$1.74 - $2.31 $760,426 - $1.01 Million	437,027 New	437,027 $922,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $259,481 - $456,811	155,378 New	155,378 $363,000
Q1 2022 May 16, 2022	SELL	$0.99 - $1.6 $112,544 - $181,889	-113,681 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.22 - $1.72 $104,957 - $147,973	-86,031 Reduced 43.08%	113,681 $138,000
Q3 2021 Nov 15, 2021	BUY	$1.2 - $1.5 $179,260 - $224,076	149,384 Added 296.82%	199,712 $273,000
Q2 2021 Aug 16, 2021	BUY	$1.25 - $1.83 $62,910 - $92,100	50,328 New	50,328 $70,000
Q4 2019 Feb 14, 2020	SELL	$1.27 - $1.54 $14,570 - $17,668	-11,473 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.15 - $1.59 $13,193 - $18,242	11,473 New	11,473 $15,000
Q1 2019 May 14, 2019	SELL	$1.01 - $1.83 $40,498 - $73,379	-40,098 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$0.98 - $1.85 $25,865 - $48,827	26,393 Added 192.58%	40,098 $40,000
Q3 2018 Nov 15, 2018	BUY	$1.76 - $6.38 $24,120 - $87,437	13,705 New	13,705 $24,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.